Actinium Pharmaceuticals公布ATNM-400数据,显示在三阴性乳腺癌中具有显著疗效,并能克服内分泌和Her2靶向治疗的耐药性,数据将在圣安东尼奥乳腺癌研讨会上展示
Actinium Pharmaceuticals公布ATNM-400数据,显示在三阴性乳腺癌中具有显著疗效,并能克服内分泌和Her2靶向治疗的耐药性,数据将在圣安东尼奥乳腺癌研讨会上展示
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.